160 related articles for article (PubMed ID: 26467767)
1. Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.
Vermet H; Raoust N; Ngo R; Esserméant L; Klieber S; Fabre G; Boulenc X
Drug Metab Dispos; 2016 Jan; 44(1):50-60. PubMed ID: 26467767
[TBL] [Abstract][Full Text] [Related]
2. Establishment of In Silico Prediction Models for CYP3A4 and CYP2B6 Induction in Human Hepatocytes by Multiple Regression Analysis Using Azole Compounds.
Nagai M; Konno Y; Satsukawa M; Yamashita S; Yoshinari K
Drug Metab Dispos; 2016 Aug; 44(8):1390-8. PubMed ID: 27208383
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.
Zuo R; Li F; Parikh S; Cao L; Cooper KL; Hong Y; Liu J; Faris RA; Li D; Wang H
Drug Metab Dispos; 2017 Feb; 45(2):198-207. PubMed ID: 28062541
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions.
Sun Y; Chothe PP; Sager JE; Tsao H; Moore A; Laitinen L; Hariparsad N
Drug Metab Dispos; 2017 Jun; 45(6):692-705. PubMed ID: 28336578
[TBL] [Abstract][Full Text] [Related]
5. Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells.
Templeton IE; Houston JB; Galetin A
Drug Metab Dispos; 2011 Oct; 39(10):1921-9. PubMed ID: 21771933
[TBL] [Abstract][Full Text] [Related]
6. Prediction of clinical CYP3A4 induction using cryopreserved human hepatocytes.
Kaneko A; Kato M; Endo C; Nakano K; Ishigai M; Takeda K
Xenobiotica; 2010 Dec; 40(12):791-9. PubMed ID: 20863202
[TBL] [Abstract][Full Text] [Related]
7. Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling Å; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 Oct; 108(4):844-855. PubMed ID: 32320483
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Kim S; Dinchuk JE; Anthony MN; Orcutt T; Zoeckler ME; Sauer MB; Mosure KW; Vuppugalla R; Grace JE; Simmermacher J; Dulac HA; Pizzano J; Sinz M
Drug Metab Dispos; 2010 Jan; 38(1):16-24. PubMed ID: 19833845
[TBL] [Abstract][Full Text] [Related]
9. Activation of the aryl hydrocarbon receptor decreases rifampicin-induced CYP3A4 expression in primary human hepatocytes and HepaRG.
Rasmussen MK; Daujat-Chavanieu M; Gerbal-Chaloin S
Toxicol Lett; 2017 Aug; 277():1-8. PubMed ID: 28571685
[TBL] [Abstract][Full Text] [Related]
10. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
Halladay JS; Wong S; Khojasteh SC; Grepper S
J Pharmacol Toxicol Methods; 2012; 66(3):270-5. PubMed ID: 22809809
[TBL] [Abstract][Full Text] [Related]
11. Selective Suppression of CYP3A4 mRNA and Enzyme Activity by Epidermal Growth Factor in Plated Human Hepatocytes.
Zhang JG; Wang D; Ho T; Clark RJ; Stresser DM
Drug Metab Lett; 2017; 11(2):119-127. PubMed ID: 29189189
[TBL] [Abstract][Full Text] [Related]
12. Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the
Kuramoto S; Kato M; Shindoh H; Kaneko A; Ishigai M; Miyauchi S
Drug Metab Dispos; 2017 Nov; 45(11):1139-1145. PubMed ID: 28821485
[TBL] [Abstract][Full Text] [Related]
13. Cryopreserved human hepatocytes as alternative in vitro model for cytochrome p450 induction studies.
Garcia M; Rager J; Wang Q; Strab R; Hidalgo IJ; Owen A; Li J
In Vitro Cell Dev Biol Anim; 2003; 39(7):283-7. PubMed ID: 14599235
[TBL] [Abstract][Full Text] [Related]
14. In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells.
Kaneko A; Kato M; Sekiguchi N; Mitsui T; Takeda K; Aso Y
Xenobiotica; 2009 Nov; 39(11):803-10. PubMed ID: 19845431
[TBL] [Abstract][Full Text] [Related]
15. A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes.
Kamiguchi N; Aoyama E; Okuda T; Moriwaki T
Drug Metab Dispos; 2010 Nov; 38(11):1912-6. PubMed ID: 20699409
[TBL] [Abstract][Full Text] [Related]
16. Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance.
Kenny JR; Ramsden D; Buckley DB; Dallas S; Fung C; Mohutsky M; Einolf HJ; Chen L; Dekeyser JG; Fitzgerald M; Goosen TC; Siu YA; Walsky RL; Zhang G; Tweedie D; Hariparsad N
Drug Metab Dispos; 2018 Sep; 46(9):1285-1303. PubMed ID: 29959133
[TBL] [Abstract][Full Text] [Related]
17. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
[TBL] [Abstract][Full Text] [Related]
19. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.
Shou M; Hayashi M; Pan Y; Xu Y; Morrissey K; Xu L; Skiles GL
Drug Metab Dispos; 2008 Nov; 36(11):2355-70. PubMed ID: 18669588
[TBL] [Abstract][Full Text] [Related]
20. Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
Xu Y; Zhou Y; Hayashi M; Shou M; Skiles GL
Drug Metab Dispos; 2011 Jul; 39(7):1139-48. PubMed ID: 21441468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
